Drug Trial Radar · NCT06877247
A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism
Last checked: Nov 19, 2026Latest source record: Mar 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5
Actual
Start
Dec 23, 2024
Primary completion
Apr 4, 2025
Study completion Oct 11, 2025
Sponsor
- Lead sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to determine the mass balance and routes of excretion of total radioactivity after the dose of \[14C\] SHR6508.
Conditions
- Secondary Hyperparathyroidism
Interventions
[14C] SHR6508 InjectionDrug
\[14C\] SHR6508 injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative excretion of radioactivityTime frame: Day 1 to Day 168.
- Percentage of parent drug and its metabolites in plasma as a percentage of total radioactive exposure (%AUC)Time frame: Day 1 to Day 6.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital of Shandong Province)
Jinan, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.